文献速递临床试验与 GCP流行病学与生物统计

维生素D补充对消化道癌症患者无复发生存的影响:AMATERASU随机临床试验

Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

AMATERASU随机双盲安慰剂对照试验在单家日本大学医院纳入417例术后I–III期消化道癌症患者,比较口服维生素D3 2000 IU/d与安慰剂的5年无复发生存。总体5年无复发生存维生素D组77% vs 安慰剂组69%(HR 0.76,95%CI 0.50–1.14,P=0.18),总体生存无显著差异;基线25(OH)D 20–40 ng/mL亚组HR 0.46(95%CI 0.24–0.86,P=0.02,交互P=0.04)。

要点

  • 术后补充维生素D3 2000 IU/d未显著改善消化道癌症患者5年无复发生存。
  • 总体5年无复发生存维生素D组77% vs 安慰剂组69%,HR 0.76(95%CI 0.50–1.14,P=0.18)。
  • 基线25(OH)D 20–40 ng/mL亚组5年无复发生存85% vs 71%,HR 0.46(95%CI 0.24–0.86,P=0.02)。

核心结论

  • 在消化道癌症患者中,与安慰剂相比,维生素D补充未使5年无复发生存获得显著改善。

研究设计与样本

  • AMATERASU试验为随机双盲安慰剂对照试验,在日本单家大学医院开展,入组于2010年1月开始、随访于2018年2月完成。
  • 纳入30至90岁、食管至直肠的消化道癌症I至III期患者;439例符合条件者中15例拒绝、7例术后排除,最终251例随机至维生素D组、166例至安慰剂组,共417例纳入分析。
  • 干预为术后首次门诊起口服维生素D胶囊2000 IU/d或安慰剂至试验结束;主要结局为无复发生存(至复发或死亡),次要结局为总生存(至任何原因死亡)。
  • 亚组按基线血清25(OH)D水平分为0至<20 ng/mL、20至40 ng/mL、>40 ng/mL;因最高基线水平组样本量小,交互检验仅在低与中基线水平组间进行。

主要发现

  • 417例随机患者平均年龄66岁,男性66%,食管癌10%、胃癌42%、结直肠癌48%;中位随访3.5年(四分位距2.3–5.3年),最长随访7.6年,随访率99.8%。
  • 复发或死亡在维生素D组50例(20%)、安慰剂组43例(26%);死亡在维生素D组37例(15%)、安慰剂组25例(15%)。
  • 5年无复发生存维生素D组77% vs 安慰剂组69%(HR 0.76,95%CI 0.50–1.14,P=0.18);5年总生存82% vs 81%(HR 0.95,95%CI 0.57–1.57,P=0.83)。
  • 基线血清25(OH)D 20–40 ng/mL亚组5年无复发生存维生素D组85% vs 安慰剂组71%(HR 0.46,95%CI 0.24–0.86,P=0.02;交互P=0.04)。
  • 骨折在维生素D组3例(1.3%)、安慰剂组5例(3.4%);尿路结石在维生素D组2例(0.9%)、安慰剂组0例。

关键数值与推荐

  • 主要结局5年无复发生存:维生素D组77% vs 安慰剂组69%,HR 0.76(95%CI 0.50–1.14,P=0.18),未达统计学显著。
  • 次要结局5年总生存:维生素D组82% vs 安慰剂组81%,HR 0.95(95%CI 0.57–1.57,P=0.83)。
  • 基线25(OH)D 20–40 ng/mL亚组5年无复发生存:维生素D组85% vs 安慰剂组71%,HR 0.46(95%CI 0.24–0.86,P=0.02;交互P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials of vitamin D supplementation for secondary prevention in patients with cancer are needed, given positive results of observational studies. OBJECTIVE: To determine whether postoperative vitamin D3 supplementation can improve survival of patients with digestive tract cancers overall and in subgroups stratified by 25-hydroxyvitamin D (25[OH]D) levels. DESIGN, SETTING, AND PARTICIPANTS: The AMATERASU trial, a randomized, double-blind, placebo-controlled trial conducted at a single university hospital in Japan. Enrollment began in January 2010 and follow-up was completed in February 2018. Patients aged 30 to 90 years with cancers of the digestive tract from the esophagus to the rectum, stages I to III, were recruited. Of 439 eligible patients, 15 declined and 7 were excluded after operation. INTERVENTIONS: Patients were randomized to receive oral supplemental capsules of vitamin D (2000 IU/d; n = 251) or placebo (n = 166) from the first postoperative outpatient visit to until the end of the trial. MAIN OUTCOMES AND MEASURES: The primary outcome was relapse-free survival time to relapse or death. The secondary outcome was overall survival time to death due to any cause. Subgroups analyzed had baseline serum 25(OH)D levels of 0 to less than 20 ng/mL, 20 to 40 ng/mL, and greater than 40 ng/mL; because of small sample size for the highest-baseline-level group, interactions were tested only between the low- and middle-baseline-level groups. RESULTS: All 417 randomized patients (mean age, 66 years; male, 66%; esophageal cancer, 10%; gastric cancer, 42%; colorectal cancer, 48%) were included in the analyses. There was 99.8% follow-up over a median 3.5 (interquartile range, 2.3-5.3) years, with maximal follow-up of 7.6 years. Relapse or death occurred in 50 patients (20%) randomized to vitamin D and 43 patients (26%) randomized to placebo. Death occurred in 37 (15%) in the vitamin D group and 25 (15%) in the placebo group. The 5-year relapse-free survival was 77% with vitamin D vs 69% with placebo (hazard ratio [HR] for relapse or death, 0.76; 95% CI, 0.50-1.14; P = .18). The 5-year overall survival in the vitamin D vs placebo groups was 82% vs 81% (HR for death, 0.95; 95% CI, 0.57-1.57; P = .83). In the subgroup of patients with baseline serum 25(OH)D levels between 20 and 40 ng/mL, the 5-year relapse-free survival was 85% with vitamin D vs 71% with placebo (HR for relapse or death, 0.46; 95% CI, 0.24-0.86; P = .02; P = .04 for interaction). Fractures occurred in 3 patients (1.3%) in the vitamin D group and 5 (3.4%) in the placebo group. Urinary stones occurred in 2 patients (0.9%) in the vitamin D group and 0 in the placebo group. CONCLUSIONS AND RELEVANCE: Among patients with digestive tract cancer, vitamin D supplementation, compared with placebo, did not result in significant improvement in relapse-free survival at 5 years. TRIAL REGISTRATION: UMIN Identifier: UMIN000001977.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Urashima M, Ohdaira H, Akutsu T, et al. Effect of Vitamin D Supplementation on Relapse-Free Survival Among Patients With Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. JAMA. 2019. PMID: 30964526. doi:10.1001/jama.2019.2210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。